Carisma Therapeutics Stock Performance
| CARM Stock | 0.85 0.01 1.19% |
The firm shows a Beta (market volatility) of 1.05, which signifies a somewhat significant risk relative to the market. Carisma Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Carisma Therapeutics is expected to follow. At this point, Carisma Therapeutics has a negative expected return of -0.22%. Please make sure to confirm Carisma Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Carisma Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Carisma Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:20 | Dividend Date 2023-03-08 | Last Split Date 2023-03-08 |
1 | Moderna, Carisma name autoimmune targets | 09/10/2024 |
2 | Importers now benefiting from new accounting system for the collection of duties and taxes for commercial goods | 10/21/2024 |
3 | Insider Trading | 10/31/2024 |
4 | Carisma Therapeutics Upgraded to Strong-Buy at EF Hutton Acquisition Co. I | 11/01/2024 |
5 | CARISMA Therapeutics Inc Reports Q3 2024 Revenue of 3.39M and GAAP EPS of -0. ... | 11/07/2024 |
6 | Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference | 11/27/2024 |
| Begin Period Cash Flow | 24.2 M |
Carisma |
Carisma Therapeutics Relative Risk vs. Return Landscape
If you would invest 100.00 in Carisma Therapeutics on September 4, 2024 and sell it today you would lose (15.00) from holding Carisma Therapeutics or give up 15.0% of portfolio value over 90 days. Carisma Therapeutics is currently does not generate positive expected returns and assumes 2.7493% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Carisma, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Carisma Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Carisma Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Carisma Therapeutics, and traders can use it to determine the average amount a Carisma Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0787
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CARM |
Estimated Market Risk
| 2.75 actual daily | 24 76% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Carisma Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Carisma Therapeutics by adding Carisma Therapeutics to a well-diversified portfolio.
Carisma Therapeutics Fundamentals Growth
Carisma Stock prices reflect investors' perceptions of the future prospects and financial health of Carisma Therapeutics, and Carisma Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Carisma Stock performance.
| Return On Equity | -3.63 | ||||
| Return On Asset | -0.56 | ||||
| Operating Margin | (3.88) % | ||||
| Current Valuation | 12.1 M | ||||
| Shares Outstanding | 41.75 M | ||||
| Price To Book | 114.10 X | ||||
| Price To Sales | 1.76 X | ||||
| Revenue | 14.92 M | ||||
| EBITDA | (85.89 M) | ||||
| Net Income | (86.88 M) | ||||
| Total Debt | 3.12 M | ||||
| Book Value Per Share | (0.27) X | ||||
| Cash Flow From Operations | (81.18 M) | ||||
| Earnings Per Share | (1.52) X | ||||
| Market Capitalization | 35.65 M | ||||
| Total Asset | 89.55 M | ||||
| Retained Earnings | (245.1 M) | ||||
| Working Capital | 64.56 M | ||||
About Carisma Therapeutics Performance
By examining Carisma Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Carisma Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Carisma Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (44.50) | (46.73) | |
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (1.20) | (1.27) | |
| Return On Assets | (0.97) | (1.02) | |
| Return On Equity | (3.27) | (3.11) |
Things to note about Carisma Therapeutics performance evaluation
Checking the ongoing alerts about Carisma Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Carisma Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Carisma Therapeutics generated a negative expected return over the last 90 days | |
| Carisma Therapeutics has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 14.92 M. Net Loss for the year was (86.88 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Carisma Therapeutics generates negative cash flow from operations | |
| Carisma Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 29.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
- Analyzing Carisma Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Carisma Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Carisma Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Carisma Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Carisma Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Carisma Therapeutics' stock. These opinions can provide insight into Carisma Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Carisma Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Carisma Stock, please use our How to Invest in Carisma Therapeutics guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Carisma Therapeutics. If investors know Carisma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Carisma Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.52) | Revenue Per Share 0.493 | Quarterly Revenue Growth (0.12) | Return On Assets (0.56) | Return On Equity (3.63) |
The market value of Carisma Therapeutics is measured differently than its book value, which is the value of Carisma that is recorded on the company's balance sheet. Investors also form their own opinion of Carisma Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Carisma Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Carisma Therapeutics' market value can be influenced by many factors that don't directly affect Carisma Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Carisma Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Carisma Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Carisma Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.